This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. World Gastroenterology Organization. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011; 20: 299-304. 10.1097/MCG.0b013e31820fb8f621961099HuntRHXiaoSDMegraudFLeon-BaruaRBazzoliFvan der MerweSWorld Gastroenterology Organization. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global GuidelineJ Gastrointestin Liver Dis20112029930410.1097/MCG.0b013e31820fb8f6Open DOISearch in Google Scholar
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F, et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64. 10.1136/gutjnl-2012-302084MalfertheinerPMegraudFO’MorainCAAthertonJAxonATRBazzoliFManagement of Helicobacter pylori infection – the Maastricht IV/Florence Consensus ReportGut2012616466410.1136/gutjnl-2012-302084Open DOISearch in Google Scholar
International Agency for Research on Cancer. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 177-240.International Agency for Research on Cancer. Infection with Helicobacter pyloriIARC Monogr Eval Carcinog Risks Hum199461177240Search in Google Scholar
IARC Helicobacter pylori Working Group (2014). Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer IARC Working Group Reports 2014; 8: 1-181.IARCHelicobacter pylori Working Group2014Helicobacter pylori Eradication as a Strategy for Preventing Gastric CancerLyon, FranceInternational Agency for Research on Cancer IARC Working Group Reports201481181Search in Google Scholar
de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607-15. 10.1016/S1470-2045(12)70137-722575588de MartelCFerlayJFranceschiSVignatJBrayFFormanDPlummerM.Global burden of cancers attributable to infections in 2008: a review and synthetic analysisLancet Oncol2012136071510.1016/S1470-2045(12)70137-7Open DOISearch in Google Scholar
Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, et al. Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20. 10.1111/j.1523-5378.2009.00738.x20302585AsakaMKatoMTakahashiSFukudaYSugiyamaTOtaHJapanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised editionHelicobacter20101512010.1111/j.1523-5378.2009.00738.xOpen DOISearch in Google Scholar
Tepeš B, Štabuc B. [Slovenian Society for Gastroenterology and Hepatology Guidelines on the management of Helicobacter pylori infection]. Guidelines on the management of Helicobacter pylori infection. [Slovenian]. Zdrav Vestn 2011; 80: 647-56.TepešBŠtabucB.[Slovenian Society for Gastroenterology and Hepatology Guidelines on the management of Helicobacter pylori infection]. Guidelines on the management of Helicobacter pylori infection. [Slovenian]Zdrav Vestn20118064756Search in Google Scholar
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353-67. 10.1136/gutjnl-2015-30925226187502SuganoKTackJKuipersEJGrahamDYEl-OmarEMMiuraSKyoto global consensus report on Helicobacter pylori gastritisGut20156413536710.1136/gutjnl-2015-309252Open DOISearch in Google Scholar
Graham DY, Dorea MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti-infe 2016; 14: 577-85. 10.1080/14787210.2016.1178065GrahamDYDoreaMP.Helicobacter pylori therapy: a paradigm shiftExpert Rev Anti-infe2016145778510.1080/14787210.2016.1178065Open DOISearch in Google Scholar
McNicholl AG, Gasbarrini A, Tepeš B, Bordin DS, Lerang F, Leja M, et al. Pan-European registry on H. pylori management (HP-EUREG). Gastroenterology 2016; 150: S875-76. 10.1016/S0016-5085(16)32952-3McNichollAGGasbarriniATepešBBordinDSLerangFLejaMPan-European registry on H. pylori management (HP-EUREG)Gastroenterology2016150S8757610.1016/S0016-5085(16)32952-3Open DOISearch in Google Scholar
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377-81. 10.1016/j.jbi.2008.08.01018929686HarrisPATaylorRThielkeRPayneJGonzalezNCondeJG.Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics supportJ Biomed Inform2009423778110.1016/j.jbi.2008.08.010270003018929686Open DOISearch in Google Scholar
Tepeš B, Vujasinović M, Šeruga M, Stefanovič M, Forte A, Jeverica S. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2016; 28: 676-83. 10.1097/MEG.000000000000059026862930TepešBVujasinovićMŠerugaMStefanovičMForteAJevericaS.Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradicationEur J Gastroenterol Hepatol2016286768310.1097/MEG.000000000000059026862930Open DOISearch in Google Scholar
Tepeš B, Zvezdana O. [Cumulative Helicobacter pylori eradication rates in Slovenia in the year 2008]. [Slovenian]. Zdrav Vestn 2010; 79: 19-24.TepešBZvezdanaO.[Cumulative Helicobacter pylori eradication rates in Slovenia in the year 2008]. [Slovenian]Zdrav Vestn2010791924Search in Google Scholar
Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53. 10.1136/gut.2009.19275720525969GrahamDYFischbachL.Helicobacter pylori treatment in the era of increasing antibiotic resistanceGut20105911435310.1136/gut.2009.19275720525969Open DOISearch in Google Scholar
McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36: 414-25. 10.1111/j.1365-2036.2012.05211.x22803691McNichollAGLinaresPMNyssenOPCalvetXGisbertJP.Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infectionAliment Pharmacol Ther2012364142510.1111/j.1365-2036.2012.05211.x22803691Open DOISearch in Google Scholar
Serrano D, Torrado S, Torrado-Santiago S, Gisbert J P. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/-pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab 2012; 13: 1303-12. 10.2174/13892001280334139322493986SerranoDTorradoSTorrado-SantiagoSGisbert JP.The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/-pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatmentsCurr Drug Metab20121313031210.2174/13892001280334139322493986Open DOISearch in Google Scholar
Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One 2013; 8: e62162. 10.1371/journal.pone.006673023646118TangHLLiYHuYFXieHGZhaiSD.Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trialsPLoS One20138e6216210.1371/journal.pone.0066730369808523840865Open DOISearch in Google Scholar
Tai WC, Lee CH, Chiou SS, Kuo CM, Kuo CH, et al. The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication. PLoS One 2014; 9: e105822. 10.1371/journal.pone.010582225141137TaiWCLeeCHChiouSSKuoCMKuoCHThe clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradicationPLoS One20149e10582210.1371/journal.pone.0105822413939825141137Open DOISearch in Google Scholar
Jeverica S, Tepeš B, Ihan A, Skvarč M. [Primary resistance of Helicobacter pylori]. [Slovenian]. Zdrav Vestn 2010; 79: 25-30.JevericaSTepešBIhanASkvarčM.[Primary resistance of Helicobacter pylori]. [Slovenian]Zdrav Vestn2010792530Search in Google Scholar
Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42. 10.1136/gutjnl-2012-30225422580412MegraudFCoenenSVersportenAKistMLopez-BreaMHirschlAMHelicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumptionGut201362344210.1136/gutjnl-2012-30225422580412Open DOISearch in Google Scholar
Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Perez-Aisa A, et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015; 41: 581-9. 10.1111/apt.1306925776067Molina-InfanteJLucendoAJAngueiraTRodriguez-TellezMPerez-AisaAOptimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON studyAliment Pharmacol Ther201541581910.1111/apt.1306925776067Open DOISearch in Google Scholar
McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons, et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014; 63: 244-9. 10.1136/gutjnl-2013-30482023665990McNichollAGMarinACMolina-InfanteJCastroMBarrioJ DuconsRandomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practiceGut201463244910.1136/gutjnl-2013-30482023665990Open DOISearch in Google Scholar
Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20: 10338-47. 10.3748/wjg.v20.i30.1033825132750Molina-InfanteJGisbertJP.Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistanceWorld J Gastroenterol201420103384710.3748/wjg.v20.i30.10338413084125132750Open DOISearch in Google Scholar
Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177-86. 10.1016/j.cgh.2013.05.02823751282GrahamDYLeeYCWuMS.Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidenceClin Gastroenterol Hepatol2014121778610.1016/j.cgh.2013.05.028383066723751282Open DOISearch in Google Scholar
Rokkas T, Sechopoulos P, Robotis I, MargantinisG, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second line regimens proposed by Maastricht III consensus and a third line empirical regimen. Am J Gastroenterol 2009; 104: 21-5. 10.1038/ajg.2008.87RokkasTSechopoulosPRobotisIMargantinisGPistiolasD.Cumulative H. pylori eradication rates in clinical practice by adopting first and second line regimens proposed by Maastricht III consensus and a third line empirical regimenAm J Gastroenterol200910421510.1038/ajg.2008.8719098844Open DOISearch in Google Scholar
